ALFACALCIDOL IN TREATMENT OF OSTEOPOROSIS


I.A. Baranova

FSBEI HE RNSMU n.a. N.I. Pirogov of RMH, Moscow
The increase in the life expectancy of people has led to an increase in the prevalence of some «age-related» diseases, including osteoporosis (OP), a systemic disease of the skeleton, accompanied by brittleness of bones. The development of OP is closely related to vitamin D deficiency. On the basis of natural vitamins D2 and D3, their active metabolites and synthetic analogues, a significant amount of vitamin products and drugs has been created in various dosage forms that are widely used to prevention and treatment not only OP but also other diseases. This article considers the potentials for the clinical use of the active metabolite alfacalcidol, a prodrug, which is activated in the liver and bone tissue with formation of D-hormone after intake. Alfacalcidol is more effective than native vitamin D, it increases the bone mineral density and its strength, regardless of calcium absorption and inhibition of parathyroid hormone activity.
It is shown that this drug reduces the incidence of falls in elderly patients. Alfacalcidol has therapeutic and prophylactic effects in various forms of OP and can be used both as monotherapy and in combination with other anti-osteoporotic drugs.

About the Autors


I.A. Baranova – MD, Prof., FSBEI HE RNSMU n.a. N.I. Pirogov of RMH, Moscow; e-mail: iribaranova@yandex.ru


Similar Articles


Бионика Медиа